Harmony Biosciences Holdings (HRMY) Invested Capital (2019 - 2026)

Harmony Biosciences Holdings has disclosed Invested Capital across 8 years of filings, most recently posting $930.3 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $930.3 million, up 26.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $930.3 million (up 26.06% YoY), and the FY2025 annual result was $890.2 million, up 31.81% from the prior year.
• Invested Capital came in at $930.3 million for Q1 2026 at Harmony Biosciences Holdings, up from $890.2 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $930.3 million in Q1 2026 to a low of $216.5 million in Q1 2022.
• The 5-year median for Invested Capital is $530.4 million (2024), against an average of $571.6 million.
• Peak annual rise in Invested Capital reached 124.57% in 2022, while the deepest fall reached 29.68% in 2022.
• Harmony Biosciences Holdings' Invested Capital stood at $404.8 million in 2022, then gained by 19.06% to $482.0 million in 2023, then soared by 40.13% to $675.4 million in 2024, then jumped by 31.81% to $890.2 million in 2025, then advanced by 4.51% to $930.3 million in 2026.
• The last three Invested Capital figures came in at $930.3 million (Q1 2026), $890.2 million (Q4 2025), and $855.1 million (Q3 2025), per Business Quant data.